127 related articles for article (PubMed ID: 37530190)
21. Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours.
Fusco P; Parisatto B; Rampazzo E; Persano L; Frasson C; Di Meglio A; Leslz A; Santoro L; Cafferata B; Zin A; Cimetta E; Basso G; Esposito MR; Tonini GP
BMC Cancer; 2019 Oct; 19(1):970. PubMed ID: 31638925
[TBL] [Abstract][Full Text] [Related]
22. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
[TBL] [Abstract][Full Text] [Related]
23. Identification of recurrent 3q13.31 chromosomal rearrangement indicates
Martinez-Monleon A; Gaarder J; Djos A; Kogner P; Fransson S
Int J Oncol; 2023 Feb; 62(2):. PubMed ID: 36601748
[TBL] [Abstract][Full Text] [Related]
24. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F
BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755
[TBL] [Abstract][Full Text] [Related]
25. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization.
Breen CJ; O'Meara A; McDermott M; Mullarkey M; Stallings RL
Cancer Genet Cytogenet; 2000 Jul; 120(1):44-9. PubMed ID: 10913676
[TBL] [Abstract][Full Text] [Related]
26. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
Spitz R; Hero B; Simon T; Berthold F
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
[TBL] [Abstract][Full Text] [Related]
27. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F
Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980
[TBL] [Abstract][Full Text] [Related]
28. Significance of chromosome 1p loss of heterozygosity in neuroblastoma.
Maris JM; White PS; Beltinger CP; Sulman EP; Castleberry RP; Shuster JJ; Look AT; Brodeur GM
Cancer Res; 1995 Oct; 55(20):4664-9. PubMed ID: 7553646
[TBL] [Abstract][Full Text] [Related]
29. Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?
Stallings RL; Howard J; Dunlop A; Mullarkey M; McDermott M; Breatnach F; O'Meara A
Cancer Genet Cytogenet; 2003 Jan; 140(2):133-7. PubMed ID: 12645651
[TBL] [Abstract][Full Text] [Related]
30. High genomic instability predicts survival in metastatic high-risk neuroblastoma.
Stigliani S; Coco S; Moretti S; Oberthuer A; Fischer M; Theissen J; Gallo F; Garavent A; Berthold F; Bonassi S; Tonini GP; Scaruffi P
Neoplasia; 2012 Sep; 14(9):823-32. PubMed ID: 23019414
[TBL] [Abstract][Full Text] [Related]
31. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
[TBL] [Abstract][Full Text] [Related]
32. Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival.
Keane S; Améen S; Lindlöf A; Ejeskär K
Cell Commun Signal; 2020 Apr; 18(1):65. PubMed ID: 32312269
[TBL] [Abstract][Full Text] [Related]
33. Chromosome 1p status in neuroblastoma correlates with higher expression levels of miRNAs targeting neuronal differentiation pathway.
Bagci O; Tumer S; Altungoz O
In Vitro Cell Dev Biol Anim; 2023 Feb; 59(2):100-108. PubMed ID: 36800078
[TBL] [Abstract][Full Text] [Related]
34. Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q.
Simon T; Spitz R; Hero B; Berthold F; Faldum A
Cancer Lett; 2006 Jun; 237(2):215-22. PubMed ID: 16019135
[TBL] [Abstract][Full Text] [Related]
35. Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell.
Mora J; Cheung NK; Juan G; Illei P; Cheung I; Akram M; Chi S; Ladanyi M; Cordon-Cardo C; Gerald WL
Cancer Res; 2001 Sep; 61(18):6892-8. PubMed ID: 11559566
[TBL] [Abstract][Full Text] [Related]
36. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma.
Spitz R; Betts DR; Simon T; Boensch M; Oestreich J; Niggli FK; Ernestus K; Berthold F; Hero B
Cancer Genet Cytogenet; 2006 May; 167(1):51-6. PubMed ID: 16682287
[TBL] [Abstract][Full Text] [Related]
37. Copy number alteration analysis for neuroblastoma using droplet digital polymerase chain reaction.
Ishii Y; Sato-Otsubo A; Takita J; Morio T; Takagi M
Pediatr Int; 2021 Oct; 63(10):1192-1197. PubMed ID: 33462952
[TBL] [Abstract][Full Text] [Related]
38. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization.
Plantaz D; Mohapatra G; Matthay KK; Pellarin M; Seeger RC; Feuerstein BG
Am J Pathol; 1997 Jan; 150(1):81-9. PubMed ID: 9006325
[TBL] [Abstract][Full Text] [Related]
39. Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes.
Fernández-Blanco B; Berbegall AP; Martin-Vañó S; Castel V; Navarro S; Noguera R
Neoplasia; 2021 Jan; 23(1):12-20. PubMed ID: 33190090
[TBL] [Abstract][Full Text] [Related]
40. Loss of heterozygosity for alleles on chromosomes 11q and 14q in neuroblastoma.
Srivatsan ES; Murali V; Seeger RC
Prog Clin Biol Res; 1991; 366():91-8. PubMed ID: 2068183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
